Identification

Name
Elbasvir
Accession Number
DB11574
Type
Small Molecule
Groups
Approved
Description

Elbasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [5]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Elbasvir. Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [Synthesis]. The barrier for develoment of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [3]. Subtitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to Elbasvir [FDA Label]. Despite this disadvantage Elbasvir is still effective against HCV particularly when paired with Grazoprevir.

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Elbasvir as first line therapy in combination with Grazoprevir for genotypes 1a, 1b, and 4 of Hepatitis C [3]. Elbasvir and Grazoprevir are used with or without Ribavirin with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [4].

Elbasvir is available as a fixed dose combination product with Grazoprevir (tradename Zepatier) used for the treatment of chronic Hepatitis C. Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without Ribavirin depending on the the presence of resistance associated amino acid substitutions in the NS5A protein and previous treatment failure with Ribavirin, Peginterferon alfa-2a, Peginterferon alfa-2b, or other NS3/4A inhibitors like Boceprevir, Simeprevir, or Telaprevir [FDA Label]. When combined together, Elbasvir and Grazoprevir as the combination product Zepatier have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment [5]. It can be used in patients with compensated cirrhosis, human immunodeficiency virus co-infection, or severe kidney disease.

Structure
Thumb
Synonyms
Not Available
External IDs
MK 8742 / MK-8742 / MK8742
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ZepatierElbasvir (50 mg) + Grazoprevir (100 mg)Tablet, film coatedOralMerck Sharp & Dohme Limited2016-07-22Not applicableEu
ZepatierElbasvir (50 mg/1) + Grazoprevir (100 mg/1)Tablet, film coatedOralMerck Sharp & Dohme Limited2016-01-28Not applicableUs
ZepatierElbasvir (50 mg) + Grazoprevir (100 mg)TabletOralMerck Ltd.2016-01-25Not applicableCanada
Categories
UNII
632L571YDK
CAS number
1370468-36-2
Weight
Average: 882.035
Monoisotopic: 881.422445147
Chemical Formula
C49H55N9O7
InChI Key
BVAZQCUMNICBAQ-PZHYSIFUSA-N
InChI
InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
IUPAC Name
methyl N-[(2S)-1-[(2S)-2-{4-[(9S)-5-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-4-yl}-9-phenyl-8-oxa-10-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(17),2(7),3,5,11(16),12,14-heptaen-14-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
SMILES
COC(=O)N[[email protected]@H](C(C)C)C(=O)N1CCC[[email protected]]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[[email protected]@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[[email protected]@H]3CCCN3C(=O)[[email protected]@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1

Pharmacology

Indication

Elbasvir, when used in combination with Grazoprevir as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label].

Structured Indications
Pharmacodynamics

Elbasvir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotypes 1a, 1b, and 4 [FDA Label].

Mechanism of action

Elbasvir is an inhibitor of the HCV non-structural protein 5A. While the precise role of this protein is unknown, it is essential to viral replication and virion assembly [Synthesis]. Potential modes of action of NS5A inhibitors like Elbasvir include blocking signaling interactions, redistribution of NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modification of the HCV replication complex [3].

TargetActionsOrganism
ANonstructural Protein 5A (NS5A)
inhibitor
Hepatitis C Virus (HCV)
Absorption

Elbasvir reaches peak plasma concentration 3-6 hours after administration [FDA Label]. Elbasvir has an absolute bioavailability of 32%. When taken with food the peak concentration of Elbasvir increases 1.5 fold but this increase in exposure has not been deemed clinically relevant.

Volume of distribution

Elbasvir has an estimated apparent volume of distribution of 680 liters [FDA Label]. It is thought to distribute into most tissues including the liver.

Protein binding

Elbasvir is more than 99.9% bound to plasma proteins [FDA Label]. It binds both human serum albumin and α1-acid glycoprotein.

Metabolism

Elbasvir is partially eliminated by oxidative metabolism meditated by CYP3A [FDA Label]. No circulating metabolites of have been detected in human plasma.

Route of elimination

Elbasvir is mainly eliminated in the feces (90%) with very little eliminated in the urine (<1%) [FDA Label].

Half life

The geometric mean apparent terminal half-life for Grazoprevir is 24 hours in HCV-infected subjects [FDA Label].

Clearance

The clearance of Elbasvir has not been determined [FDA Label].

Toxicity

The most commonly reported adverse reactions of all intensity (greater than or equal to 5% in placebo-controlled trials) were fatigue, headache, and nausea [FDA Label].

Affected organisms
  • Hepatitis C Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Elbasvir.Approved
AcetaminophenThe serum concentration of Elbasvir can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Elbasvir.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Elbasvir.Approved
AlbendazoleThe serum concentration of Elbasvir can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Elbasvir.Experimental
AlectinibThe serum concentration of Elbasvir can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Elbasvir can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Elbasvir.Approved, Investigational
AmantadineThe serum concentration of Elbasvir can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Elbasvir.Approved, Investigational
Aminohippuric acidThe serum concentration of Elbasvir can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Elbasvir can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Elbasvir can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Elbasvir can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Elbasvir can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Elbasvir can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Elbasvir.Approved
AprepitantThe serum concentration of Elbasvir can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Elbasvir.Approved, Investigational
AstemizoleThe serum concentration of Elbasvir can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Elbasvir can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Elbasvir can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Elbasvir can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Elbasvir is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Elbasvir.Approved, Investigational
AzelastineThe serum concentration of Elbasvir can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Elbasvir can be increased when it is combined with Azithromycin.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Elbasvir.Approved, Investigational
BenzocaineThe serum concentration of Elbasvir can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Elbasvir can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Elbasvir.Approved, Vet Approved
BiperidenThe serum concentration of Elbasvir can be increased when it is combined with Biperiden.Approved
BoceprevirThe metabolism of Elbasvir can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Elbasvir can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Elbasvir can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Elbasvir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Elbasvir.Approved
BromocriptineThe serum concentration of Elbasvir can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Elbasvir can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Elbasvir can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Elbasvir can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Elbasvir.Approved
CaffeineThe serum concentration of Elbasvir can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Elbasvir.Experimental
CanagliflozinThe serum concentration of Elbasvir can be increased when it is combined with Canagliflozin.Approved
Candesartan cilexetilThe serum concentration of Elbasvir can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Elbasvir can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Elbasvir can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Elbasvir.Approved
CarvedilolThe serum concentration of Elbasvir can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Elbasvir can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Elbasvir can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Elbasvir.Withdrawn
ChloroquineThe serum concentration of Elbasvir can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Elbasvir can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Elbasvir can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Elbasvir can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Elbasvir can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Elbasvir can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Elbasvir can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Elbasvir can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Elbasvir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Elbasvir.Approved
CitalopramThe serum concentration of Elbasvir can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Elbasvir can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Elbasvir can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Elbasvir.Approved, Illicit
ClofazimineThe serum concentration of Elbasvir can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Elbasvir.Approved, Investigational
ClomipramineThe serum concentration of Elbasvir can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Elbasvir.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Elbasvir.Approved, Nutraceutical
ClotrimazoleThe metabolism of Elbasvir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Elbasvir.Approved
CobicistatThe metabolism of Elbasvir can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Elbasvir.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Elbasvir.Approved
ColforsinThe serum concentration of Elbasvir can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Elbasvir can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Elbasvir.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Elbasvir.Approved
CrizotinibThe serum concentration of Elbasvir can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Elbasvir can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Elbasvir can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Elbasvir.Approved
DabrafenibThe serum concentration of Elbasvir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Elbasvir can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Elbasvir can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Elbasvir.Approved
DarunavirThe metabolism of Elbasvir can be decreased when combined with Darunavir.Approved
DaunorubicinThe serum concentration of Elbasvir can be increased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Elbasvir.Approved
DeferasiroxThe serum concentration of Elbasvir can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Elbasvir can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Elbasvir can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Elbasvir can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Elbasvir can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Elbasvir can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Elbasvir.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Elbasvir can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Elbasvir.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Elbasvir.Approved
DigoxinThe serum concentration of Elbasvir can be increased when it is combined with Digoxin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Elbasvir.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Elbasvir.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Elbasvir.Experimental
DihydroergotamineThe metabolism of Elbasvir can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Elbasvir.Illicit
DiltiazemThe serum concentration of Elbasvir can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Elbasvir can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Elbasvir.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Elbasvir.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Elbasvir can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Elbasvir can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Elbasvir.Approved, Investigational
DoxycyclineThe metabolism of Elbasvir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Elbasvir can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Elbasvir can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Elbasvir.Approved, Investigational
EnalaprilThe serum concentration of Elbasvir can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Elbasvir.Approved
EnzalutamideThe serum concentration of Elbasvir can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Elbasvir.Approved, Investigational
ErgonovineThe serum concentration of Elbasvir can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Elbasvir can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Elbasvir.Approved, Investigational
ErythromycinThe serum concentration of Elbasvir can be increased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Elbasvir.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Elbasvir can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Elbasvir.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Elbasvir.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Elbasvir.Approved
EtoposideThe serum concentration of Elbasvir can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Elbasvir can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Elbasvir.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Elbasvir.Approved
FelodipineThe serum concentration of Elbasvir can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Elbasvir can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Elbasvir.Approved
FexofenadineThe serum concentration of Elbasvir can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Elbasvir can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe metabolism of Elbasvir can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of Elbasvir can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Elbasvir can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Elbasvir can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Elbasvir can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Elbasvir.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Elbasvir.Approved
FluvoxamineThe metabolism of Elbasvir can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Elbasvir can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Elbasvir can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Elbasvir can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Elbasvir can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Elbasvir can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Elbasvir.Approved
GenisteinThe serum concentration of Elbasvir can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Elbasvir.Approved
GlyburideThe serum concentration of Elbasvir can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Elbasvir can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Elbasvir can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Elbasvir.Approved
GrepafloxacinThe serum concentration of Elbasvir can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Elbasvir can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Elbasvir can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Elbasvir.Approved
IdelalisibThe serum concentration of Elbasvir can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Elbasvir can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Elbasvir can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Elbasvir.Approved
IndinavirThe metabolism of Elbasvir can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Elbasvir can be increased when it is combined with Indomethacin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Elbasvir.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Elbasvir.Approved, Investigational
IsavuconazoniumThe metabolism of Elbasvir can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Elbasvir can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Elbasvir can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Elbasvir can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Elbasvir can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Elbasvir can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Elbasvir.Approved
KetoconazoleThe metabolism of Elbasvir can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Elbasvir.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Elbasvir.Approved, Investigational
LansoprazoleThe serum concentration of Elbasvir can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Elbasvir can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Elbasvir.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Elbasvir.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Elbasvir.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Elbasvir.Approved, Investigational
LevofloxacinThe serum concentration of Elbasvir can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Elbasvir.Approved
LevothyroxineThe serum concentration of Elbasvir can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Elbasvir can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Elbasvir.Approved
LiothyronineThe serum concentration of Elbasvir can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Elbasvir can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Elbasvir can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Elbasvir.Approved
LomitapideThe serum concentration of Elbasvir can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Elbasvir can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Elbasvir can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Elbasvir can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Elbasvir can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Elbasvir can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Elbasvir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Elbasvir can be decreased when it is combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Elbasvir.Illicit, Withdrawn
MannitolThe serum concentration of Mannitol can be increased when it is combined with Elbasvir.Approved, Investigational
MaprotilineThe serum concentration of Elbasvir can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Elbasvir can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Elbasvir can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Elbasvir can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Elbasvir can be increased when it is combined with Meprobamate.Approved, Illicit
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Elbasvir.Experimental
MethadoneThe serum concentration of Elbasvir can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Elbasvir.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Elbasvir.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Elbasvir.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Elbasvir.Approved
MetoprololThe serum concentration of Elbasvir can be increased when it is combined with Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Elbasvir.Experimental
MibefradilThe serum concentration of Elbasvir can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Elbasvir can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Elbasvir can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Elbasvir can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Elbasvir.Approved
MitomycinThe serum concentration of Elbasvir can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Elbasvir can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Elbasvir can be increased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Elbasvir can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Elbasvir.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Elbasvir.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Elbasvir.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Elbasvir.Approved, Vet Approved
NaltrexoneThe serum concentration of Elbasvir can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Elbasvir can be increased when it is combined with Naringenin.Experimental
NefazodoneThe metabolism of Elbasvir can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Elbasvir can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Elbasvir can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Elbasvir can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Elbasvir can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Elbasvir can be increased when it is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Elbasvir.Approved
NifedipineThe serum concentration of Elbasvir can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Elbasvir can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Elbasvir.Approved
NisoldipineThe serum concentration of Elbasvir can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Elbasvir can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Elbasvir can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Elbasvir.Approved
NorethisteroneThe serum concentration of Elbasvir can be decreased when it is combined with Norethisterone.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Elbasvir.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Elbasvir.Approved, Investigational
OlaparibThe metabolism of Elbasvir can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Elbasvir.Approved
OmeprazoleThe serum concentration of Elbasvir can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Elbasvir can be increased when it is combined with Osimertinib.Approved
P-NitrophenolThe serum concentration of Elbasvir can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Elbasvir can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Elbasvir can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Elbasvir can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Elbasvir.Approved, Investigational
PantoprazoleThe serum concentration of Elbasvir can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Elbasvir can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Elbasvir.Approved
PentobarbitalThe metabolism of Elbasvir can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Elbasvir.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Elbasvir can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Elbasvir can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Elbasvir can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Elbasvir.Approved
PimozideThe serum concentration of Elbasvir can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Elbasvir.Approved
Platelet Activating FactorThe serum concentration of Elbasvir can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Elbasvir.Approved
PonatinibThe serum concentration of Elbasvir can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Elbasvir can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Elbasvir can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Elbasvir can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Elbasvir.Approved, Vet Approved
PrednisoneThe serum concentration of Elbasvir can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Elbasvir can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Elbasvir can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Elbasvir can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Elbasvir can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Elbasvir can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Elbasvir can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Elbasvir can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Elbasvir.Approved
QuercetinThe serum concentration of Elbasvir can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Elbasvir.Approved
QuinacrineThe serum concentration of Elbasvir can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Elbasvir can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Elbasvir can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Elbasvir can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Elbasvir.Approved, Investigational
ReboxetineThe serum concentration of Elbasvir can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Elbasvir can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Elbasvir can be increased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Elbasvir can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Elbasvir can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Elbasvir can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Elbasvir.Approved, Investigational
RilpivirineThe serum concentration of Elbasvir can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Elbasvir.Approved, Investigational
RitonavirThe metabolism of Elbasvir can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Elbasvir.Approved
RolapitantThe serum concentration of Elbasvir can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Elbasvir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Elbasvir.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Elbasvir.Approved, Vet Approved
SaquinavirThe metabolism of Elbasvir can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Elbasvir can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Elbasvir can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Elbasvir.Approved
SertralineThe serum concentration of Elbasvir can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Elbasvir can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Elbasvir.Approved
SiltuximabThe serum concentration of Elbasvir can be decreased when it is combined with Siltuximab.Approved
SirolimusThe serum concentration of Elbasvir can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Elbasvir.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Elbasvir.Approved
SorafenibThe serum concentration of Elbasvir can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Elbasvir.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Elbasvir.Experimental
SpironolactoneThe serum concentration of Elbasvir can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Elbasvir can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Elbasvir can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Elbasvir can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Elbasvir can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Elbasvir can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Elbasvir can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Elbasvir can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Elbasvir can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Elbasvir can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Elbasvir can be increased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Elbasvir can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Elbasvir can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Elbasvir.Approved
TelaprevirThe metabolism of Elbasvir can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Elbasvir can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Elbasvir can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Elbasvir can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Elbasvir can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Elbasvir can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Elbasvir.Experimental
TesmilifeneThe serum concentration of Elbasvir can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Elbasvir can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Elbasvir can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Elbasvir can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Elbasvir.Approved
TocilizumabThe serum concentration of Elbasvir can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Elbasvir can be increased when it is combined with Tolvaptan.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Elbasvir.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Elbasvir.Approved
TrazodoneThe serum concentration of Elbasvir can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Elbasvir can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Elbasvir can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Elbasvir can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Elbasvir can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Elbasvir can be increased when it is combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Elbasvir.Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Elbasvir.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Elbasvir.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Elbasvir.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Elbasvir.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Elbasvir.Approved
VenlafaxineThe serum concentration of Elbasvir can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Elbasvir can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Elbasvir can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Elbasvir.Approved, Investigational
VinorelbineThe serum concentration of Elbasvir can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Elbasvir.Approved
VoriconazoleThe metabolism of Elbasvir can be decreased when combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Elbasvir.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Elbasvir.Approved
ZimelidineThe serum concentration of Elbasvir can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Elbasvir can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference

Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW: Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40. doi: 10.1002/cmdc.201300343. Epub 2013 Oct 14.

General References
  1. Bell AM, Wagner JL, Barber KE, Stover KR: Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. Int J Hepatol. 2016;2016:3852126. doi: 10.1155/2016/3852126. Epub 2016 Jun 15. [PubMed:27403342]
  2. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW: Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40. doi: 10.1002/cmdc.201300343. Epub 2013 Oct 14. [PubMed:24127258]
  3. Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [PubMed:28497432]
  4. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348]
  5. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
External Links
KEGG Drug
D10625
ChemSpider
30843797
ChEBI
132967
ChEMBL
CHEMBL3039514
PharmGKB
PA166163436
RxList
RxList Drug Page
Wikipedia
Elbasvir
AHFS Codes
  • 08:18.40.24 — HCV Replication Complex Inhibitors
FDA label
Download (441 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentChronic Hepatitis C Infection / Transplant, Kidney1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Impaired Renal Function1
1CompletedTreatmentHepatic Insufficiency1
1CompletedTreatmentHepatitis, Viral, Human1
1, 2RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
1, 2RecruitingTreatmentHeart Failure, Unspecified1
2CompletedTreatmentChronic Hepatitis C Infection7
2CompletedTreatmentHepatitis C Virus (HCV)1
2RecruitingTreatmentAcute Hepatitis C / Human Immunodeficiency Virus (HIV)1
2, 3CompletedTreatmentChronic Hepatitis C Infection1
2, 3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2, 3CompletedTreatmentHepatitis C Virus (HCV)1
3CompletedTreatmentChronic Hepatitis C Infection2
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3CompletedTreatmentHepatitis C Infection1
3Not Yet RecruitingTreatmentChronic HCV Infection1
3Not Yet RecruitingTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
3Not Yet RecruitingTreatmentChronic Hepatitis C Infection / Transplantation, Liver1
3Not Yet RecruitingTreatmentChronic Hepatitis C Infection / Compensated liver disease1
3Not Yet RecruitingTreatmentChronic hepatitis C genotype 1b / Cirrhoses, Liver / Fibrosis, Liver / Metabolic Syndromes1
3RecruitingTreatmentAcute Hepatitis C / Chronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
3RecruitingTreatmentHepatitis C, Chronic1
3WithdrawnTreatmentChronic Hepatitis C Infection1
4Active Not RecruitingTreatmentChronic Hepatitis C Infection / End-Stage Renal Disease (ESRD)1
4Enrolling by InvitationTreatmentChronic Hepatitis C Infection / Substance Abuse, Intravenous / Substance Use Disorder (SUD)1
4Not Yet RecruitingPreventionChronic Hepatitis C Infection / Renal Failure Chronic1
4Not Yet RecruitingTreatmentChronic Hepatitis C Infection2
4Not Yet RecruitingTreatmentTo Assess the Efficacy of Grazoprevir 100mg and Elbasvir 50mg by Determining the Proportion of Sustained Virological Response 12 Weeks After the End of Therapy1
4RecruitingPreventionRenal Failure1
4RecruitingTreatmentChronic Hepatitis C Infection1
4RecruitingTreatmentChronic Hepatitis C Infection / Disorder of Transplanted Kidney / Renal Insufficiency,Chronic1
4RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection2
4SuspendedPreventionCardiac Transplant Disorder / Chronic Hepatitis C Infection1
4WithdrawnTreatmentHCV1
Not AvailableNot Yet RecruitingTreatmentHCV, HCC1
Not AvailableRecruitingNot AvailableChronic Hepatitis C Infection1
Not AvailableRecruitingNot AvailableHepatitis C, Chronic / Human Immunodeficiency Virus (HIV)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8871759No2011-05-042031-05-04Us
US7973040No2009-07-242029-07-24Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0044 mg/mLALOGPS
logP6.17ALOGPS
logP7.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)5.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area188.8 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity241.02 m3·mol-1ChemAxon
Polarizability98.71 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Valine and derivatives
Alternative Parents
Alpha amino acid amides / Indoles / N-acylpyrrolidines / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Pyrroles / Heteroaromatic compounds / Imidazoles / Methylcarbamates / Organic carbonic acids and derivatives
show 7 more
Substituents
Valine or derivatives / Alpha-amino acid amide / Indole / Indole or derivatives / N-acylpyrrolidine / Monocyclic benzene moiety / Benzenoid / Methylcarbamate / Azole / Imidazole
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

1. Nonstructural Protein 5A (NS5A)
Kind
Protein
Organism
Hepatitis C Virus (HCV)
Pharmacological action
Yes
Actions
Inhibitor

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on April 07, 2016 10:37 / Updated on October 21, 2017 19:34